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Abstract
Background: The treatment of idiopathic full-thickness macular holes involves surgery to close the hole. Some
surgeons advise patients to adopt a face-down position to increase the likelihood of successful macular hole
closure. However, patients often find the face-down positioning arduous. There is a lack of conclusive evidence
that face-down positioning improves the outcome. The ‘Positioning In Macular hole Surgery’ (PIMS) trial will assess
whether advice to position face-down after surgery improves the surgical success rate for the closure of large
(≥400 μm) macular holes.
Methods/design: The PIMS trial is a multicentre, parallel-group, superiority clinical trial with 1:1 randomisation.
Patients (n = 192) with macular holes (≥400 μm) will be randomised after surgery to either face-down positioning
or face-forward positioning for at least 8 h (which can be either consecutive or nonconsecutive) a day, for 5 days
following surgery. Inclusion criteria are: presence of an idiopathic full-thickness macular hole ≥400 μm in diameter,
as measured by optical coherence tomography (OCT) scans, on either or both eyes; patients electing to have
surgery for a macular hole, with or without simultaneous phacoemulsification and intraocular lens implant; ability
and willingness to position face-down or in an inactive face-forward position; a history of visual loss suggesting a
macular hole of 12 months’ or less duration. The primary outcome is successful macular hole closure at 3 months
post surgery. The treatment effect will be reported as an odds ratio with 95% confidence interval, adjusted for size
of macular hole and phakic lens status at baseline. Secondary outcome measures at 3 months are: further surgery
for macular holes performed or planned (of those with unsuccessful closure); patient-reported experience of
positioning; whether patients report they would still have elected to have the operation given what they know
at follow-up; best-corrected visual acuity (BCVA) measured using Snellen charts at a standard distance of 6 m;
patient-reported health and quality of life assessed using the National Eye Institute Visual Function Questionnaire
(VFQ-25).
Discussion: The PIMS trial is the first multicentre randomised control trial to investigate the value of face-down
positioning following macular hole standardised surgery.
Trial registration: International Standard Randomised Controlled Trials Number registry, ID: ISRCTN12410596.
Registered on 11 February 2015.
United Kingdom Clinical Research Network, ID: UKCRN17966. Registered on 26 November 2014.
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Overview
Purpose and scope of statistical analysis plan (SAP)
The aim of this paper is to report, in detail, the
planned analyses that were approved by the Trial
Steering Committee for the principal research for the
PIMS (Positioning In Macular hole Surgery) trial, a
multicentre, interventional, comparative, randomised
controlled clinical trial comparing face-down with
face-forward positioning on the outcome for surgery
for large macular holes. The PIMS trial is registered
with ISRCTN, number 12410596 and the UKCRN
portfolio, number 17966. The pilot study preceding
PIMS was published in Eye, 2011 [1]. This pilot rando-
mised controlled trial (RCT) explored the feasibility of
a definitive trial to determine the value of face-down
positioning following vitrectomy, internal limiting
membrane (ILM) peeling, and C3F8 gas tamponade for
full-thickness macular holes, without simultaneous
phacoemulsification. The PIMS study protocol was
published in Trials, 2015 [2]. We aim to maximise
transparency of the planned analysis with the intention
of eradicating misreporting or selective reporting of
the trial data. We have also considered any contin-
gences, with regards to specifying alternative analysis
plans if statistical models fail to converge.
This analysis plan was written, reviewed and signed
off prior to database lock, and prior to any member of
the trial team having access to unmasked trial data.
Changes from the published protocol
The protocol published in Trials stated that the analysis
for the primary outcome would be adjusted for age and
sex as fixed effects, and site as a random effect [2].
Opinion leaders questioned whether age and sex were
associated with successful macular hole closure. A brief
literature review highlighted a relevant study which did
not find a significant association between age or sex and
successful macular hole closure [3].
At the suggestion of the independent Trial Steering
Committee (TSC) the PIMS management team decided
to remove age and sex as covariates and to specify in-
stead that the primary outcome would be adjusted for
macular hole size (μm) and phakic lens status, with site
as a random effect.
Background and trial design
Further details of the rationale, treatment polices and de-
sign of the PIMS study are given in the study protocol.
In summary, idiopathic macular holes (macular holes)
cause patients’ central vision to be blurred or distorted.
Macular holes have an estimated annual incidence of 8
per 1000 individuals per year [4].
Macular holes can be treated surgically by removing
the vitreous gel from the eye (vitrectomy), peeling off
the ILM and then injection of a temporary gas bubble
into the back of the eye. Surgery is deemed successful
when the macular hole is fully closed. The current lack
of evidence with which to guide patients has led to a
lack of consensus among clinicians and wide variation
in clinical practice. Patients are understandably con-
fused and distressed by uncertainty and inconsistent
advice.
Some surgeons advise patients to adopt a face-down
position for a period immediately following surgery with
the aim of improving the outcome by maintaining
contact of the gas bubble with the macular hole. The
duration of the face-down position varies among sur-
geons. However, maintaining the face-down position can
be arduous for patients [5] and is associated with serious
adverse events. Furthermore, evidence that face-down
position treatment policy increases the closure rates of
macular holes is lacking.
Main objectives
The PIMS trial aims to determine whether the advice to
position face-down improves the surgical success rate
for closure of large (≥400 μm) macular holes, and
thereby reduces the need for further surgery. This trial
will benefit patients by providing robust evidence on the
value of posturing following surgery for large macular
holes, and enable health care providers and patients to
make an informed choice for the best positioning to
adopt after surgery.
Trial design
The PIMS trial is a multicentre, parallel-group, superiority
clinical trial with 1:1 randomisation. The trial will recruit
192 participants having surgery for large macular holes
(≥400 μm), who will be randomly allocated into one of the
two treatment arms:
1. Face-down positioning: subjects will be advised to
maintain a face-down position for a total of at least
eight consecutive or nonconsecutive hours a day for
5 days following surgery
2. Face-forward positioning: subjects will be advised to
maintain a face-forward position, inactive, for at
least eight consecutive or nonconsecutive hours a
day for 5 days following surgery
Participants
The PIMS trial is being conducted at nine hospitals in
the UK.
Patients are deemed eligible to participate in the study
if they meet the following inclusion criteria:
1. The presence of idiopathic full-thickness macular
hole, ≥400 μm in diameter as measured by optical
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coherence tomography (OCT) scans, on either or
both eyes
2. Patients electing to have surgery for macular hole,
with or without simultaneous phacoemulsification
and intraocular lens implant
3. Ability and willingness to position face-down or in
an inactive face-forward position
4. Patients with a history of visual loss suggesting a
macular hole of 12 months’ or less duration
Patients are deemed ineligible to participate in the
study if they meet one or more of the following exclusion
criteria:
1. Age-related macular degeneration, glaucoma,
diabetic retinopathy, retinal degeneration; amblyopia;
previous vitrectomy surgery (refractive error, lens
opacity, and previous use of ocriplasmin are not
exclusion criteria)
2. Traumatic macular hole
3. History of visual loss suggesting macular hole
duration longer than 12 months
4. The presence of retinal tear identified during surgery
for which postoperative positioning is advised
Outcome measures
The primary outcome of the study is the anatomical
closure of the macular hole at 3 months post surgery.
Successful closure of the macular hole will be deter-
mined by OCT scans. The scans will be anonymised and
sent to two independent retinal surgeons who will inde-
pendently grade the macular hole as closed; ‘open and
flat’ (without a cuff of subretinal fluid); or ‘open and
elevated’ (with cuff of subretinal fluid). The readers will
be masked to the identity and allocated treatment of the
subject. In the event of any disparity in grading, a third
independent retinal surgeon, also masked to identify and
treatment allocation, will arbitrate.
The categories ‘open and flat’ (without a cuff of sub-
retinal fluid), or ‘open and elevated’ (with a cuff of sub-
retinal fluid) will be pooled into one category of ‘open’
for the purpose of analysis.
Secondary outcomes at 3 months post surgery are:
 Further surgery for macular holes, performed or
planned (yes/no)
 Best-corrected visual acuity (BCVA) measured
using a Snellen chart at a standard distance of 6 m
 Patient-reported experience of positioning on a
scale from 0 (very difficult) to 10 (very easy)
 Patient-reported health and quality of life assessed
using the National Eye Institute Visual Function
Questionnaire (VFQ-25) from 0 (worst health and
quality of life) to 100 (best health and quality of life)
 Patient-reported outcome ‘Given what you now
know, would you still have elected to have the
operation?’ with responses Yes, No or Don’t Know
Sample size and randomisation
Unit of analysis
All ocular assessments relate to the study eye. In the
event that a subject is having surgery for bilateral macu-
lar holes (which are not operated on simultaneously),
the first eye to be operated on during the trial will be
the study eye.
Sample size
Clinical consensus is that face-down positioning would
be recommended if there were a difference of 15% in
success rates. This is the smallest clinically relevant
treatment difference that we wish to detect. Previous re-
search [6] indicates that successful closure of large
macular holes without advice to position face-down oc-
curs in 80% of cases. A study with 86 patients per group
has 85% power and 95% confidence to detect a difference
in outcome rate of 80% in the face-forward positioning
arm versus 95% in the face-down positioning arm. With
an anticipated 10% loss to follow-up, we are aiming to
recruit 96 patients in each arm.
Screening
The PIMS trial did not collect data on the number of
participants screened for eligibility. The reason for this
omission is that the proportion of patients with macular
holes ≥400 μm in size is a small minority of the overall
number of patients presenting with macular holes. For
some hospital sites, the data collection of the number
of patients screened for eligibility was considered un-
feasible given their current resources.
Randomisation and masking
Patients are randomised in a 1:1 ratio to follow either a
face-forward positioning or a face-down positioning.
Randomisation is stratified by site, using random per-
muted blocks of size 4 or 6 in equal proportions. A se-
cure bespoke online randomisation service implemented
by the Pragmatic Clinical Trials Unit performs the ran-
domisation. Randomisation is conducted post surgery to
ensure masking the surgeon to the treatment allocated.
Post surgery, trial staff input the patient’s ID and details
for immediate on-screen randomisation. Randomisation
is provided 7 days a week, 24 h a day. Each site is pro-
vided with a unique log-in username and password to
access the service. Due to the open-label nature of the
treatment, postoperative clinical staff and patients are
unmasked to the treatment allocation.
Investigators assessing the primary endpoint by grading
of the OCT scans are masked to the treatment allocation.
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In the event of any disagreement between the two
clinician grades, a third independent retinal surgeon,




The primary analysis for each outcome will be by
intention-to-treat, meaning that all patients on whom an
outcome is available will be included in the analysis, and
will be analysed according to the treatment group to
which they were randomised.
Through vigilance and careful planning, the PIMS trial
management team aim to achieve complete capture of
all data from all patients, including patients who do not
adhere to the protocol or patients who withdrawal from
the trial. We acknowledge that despite our best efforts,
some patients may have missing data. In accordance
with the intention-to-treat principle and to avoid con-
cerns over data-driven selection methods, we state the
plan for dealing with missing data here.
Missing data is a potential source of bias, and the ex-
tent and pattern of missing data can influence the inter-
pretation of the trial. The sample size for the PIMS trial
allows for a 10% loss of follow-up, and in our results we
will provide a full listing of all the reasons for patients’
withdrawal of the study. This list will be helpful in justi-
fying the assumptions that we make in regards to miss-
ing data; however, we cannot be certain that there is a
relationship between observed covariates and missing
outcome data, and cannot exclude the possibility of
some data missing not at random.
We will analyse the data without undertaking any sen-
sitivity analysis if the primary outcome is missing in
fewer than 5% of cases (nine patients or less). If more
than nine patients’ primary outcome is missing, we will
undertake sensitivity analysis to test if the missing at
random assumptions are appropriate. We will use a
pattern-mixture approach to model the consequences of
a systematic difference between missing and nonmissing
values, to see if the conclusions drawn from the PIMS
study are affected when the missing-at-random assump-
tion is violated.
All analyses will be performed using Stata (Stata
Corporation, College Station, TX, USA).
Variables measured and schedule of assessments
 The variables measured preoperatively are age, sex,
ethnicity, laterality, duration of symptoms, BCVA
(Best-corrected Visual Acuity), lens status
(either phakic or pseudophakic), macular hole
diameter on OCT scans and the Quality of Life
VFQ-25 questionnaire
 The variables measured at 3 months postoperatively
are BCVA, macular hole status (closed; open flat
or open elevated), the Quality of Life VFQ-25
questionnaire, subject-reported experience of
positioning and, if primary repair of a macular hole
failed, was a second operation performed or
planned?
For each comparison of outcomes according to posi-
tioning policy, the following summaries will be provided
(see templates for tables in Additional file 1):
 The number of patients in each positioning policy
group who are included in the analysis
 A summary measure of the outcome, by positioning
policy group (mean and standard deviation (SD) for
continuous outcomes, number and percentage in
each category for categorical outcomes). The
treatment effect (difference in means for continuous
outcomes, odds ratio for binary outcomes) with its
95% confidence interval (95% CI) and p value
All comparisons will adjust for linear effect of macular
hole size (μm) at baseline, phakic lens status at baseline,
and a random effect of site (hospital). We will anonymise
data reported by hospital site. Outcomes which are also
assessed at baseline (BCVA and quality of life) will be ana-
lysed adjusting also for a linear effect of the baseline
measurement.
Patients have a 2-week postoperative appointment, at
which time clinicians may be able to identify that the
macular hole closure was unsuccessful, meaning that a
second operation to close the hole is required. The out-
come of any participant who had a second surgery after
randomisation but before the 3-month visit will be im-
puted as open, as it is most unlikely that the hole will
close without further treatment by 3 months. These pa-
tients will not be completing secondary questionnaires.
Participants
We will report numbers of participants consented, ran-
domised, and followed up in a Consolidated Standards
of Reporting Trials (CONSORT) flowchart (Fig. 1). At
the time of writing this SAP, recruitment of patients is
on-going, and the trial teams remain unmasked; there-
fore, the aggregated values for the CONSORT flowchart
are not provided here.
Baseline characteristics (variables measured preopera-
tively) will be summarised by positioning policy group.
For continuous variables, we will examine the distribu-
tion of the data for symmetry, and report either the
mean and SD, or the median and interquartile range
(IQR) values. For categorical variables we will report the
number and percentage in each category for categorical
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variables, with a note of numbers with missing data if
any (see Additional file 1: Table S1).
Analysis of primary outcome
This will be analysed using mixed-effects logistic regres-
sion. This analysis will be performed by the command
xtlogit in Stata 14:
xtset site
xtlogit machole randgrp machsize i.lenstat,
re
If the mixed regression model fails to converge, we will
model site as a fixed effect rather than a random effect
with the following command:
xtlogit machole randgrp machsize i.lenstat,
fe
We will ensure that the quadrature approximation in
our model is adequate and stable. First, we will run the
command quadchk to test if our model is sensitive to
changes in the number of adaptive points [7]. If the rela-
tive differences in our coefficients change by more than
1%, we will improve the quadrature approximation by
increasing the number of integration points until this
difference in coefficients is less than 1%. If this approach
is not successful in achieving stable quadrature approxi-
mation, we will consider the command gllamm [8]
which allows for adaptive quadrature numerical integra-
tion with the following command:
gllamm machole randgrp machsize i.lenstat,
i(site) family(binom) link(logit) adapt
Analyses of secondary outcomes
For the analysis of further surgery for macular holes,
performed or planned, we will use logistic regression
(xtlogit). Best-corrected visual acuity (BCVA), measured
using Snellen charts at a standard distance of 6 m, will
be transformed to a LogMAR scale with two decimal
places [9], and then analysed using linear regression
(xtreg). Measurements of BCVA corresponding to count
fingers (CF), hand movements (HM), perception of light
(PL), and no perception of light (NPL) will be replaced
with values of 2.10, 2.40, 2.70, and 3.00, respectively.
The number of patients in each BCVA category and
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart for the Positioning In Macular hole Surgery (PIMS) trial, with expected
numbers at each stage
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their corresponding numerical values will be tabulated
by treatment arm. For the patient-reported experience of
positioning at 3 months, which is on the scale 0 (very
difficult) to 10 (very easy) we will remain masked to
treatment arm and consider an applicable cut-off value
to dichotomise this variable and then use logistic regres-
sion (xtlogit). For the patient-reported outcome ‘Given
what you know now, would you still have elected to have
the operation?’ we will pool the responses ‘Don’t know’
and ‘No’ into one category, and use logistic regression
(xtlogit). If the proportion of ‘Don’t know’ responses ex-
ceeds 10% (19 patients) we will undertake a sensitivity
analysis by pooling the ‘Don’t know’ with ‘Yes’ re-
sponses and compare how this alternative pooling af-
fects the odds ratio estimate. The Complications of
Age-related Macular Degeneration Prevention Trial
Research Group [10] observed a skewed distribution of
the VFQ-25 score; therefore, we will assume that our
results will be similarly skewed, and perform a logistic
transformation (log(x/(100 − x))) of the VFQ-25 scores,
and with this transformed outcome use linear regres-
sion (xtreg). When adjusting analyses of BCVA and
VFQ-25 for their respective baselines we will use the
same normalising transformation for the baseline
measurement as for the follow-up measurement.
Interim analyses
The PIMS Trial Steering Committee is made up of a
chair, a second clinician, an independent statistician, and
a lay member. There is no Data Monitoring Committee
(DMC) nor any planned interim analyses for this trial
due to the relatively short time span of follow-up, and
minimal clinical risks. Following the guidance in the
MRC’s updated terms of reference for Trial Steering
Committees [11], if circumstance arise that concern the
TSC, an emergency DMC, made up of independent
members, will convene to review the unblinded data and
advise the TSC.
Serious adverse events
Serious adverse events (SAE), as defined in the protocol,
will be tabulated and reported. The chief investigator
will class the SAE as Related, which is resulting from
administration of any research procedures, and/or Unex-
pected, that is not listed in the protocol as an expected
occurrence.
Trial status
Recruitment began in May 2015, with nine UK hospitals
participating in the trial. At the time of manuscript sub-
mission, November 2016, the PIMS trial is open to
recruitment.
Additional file
Additional file 1: Templates for PIMS results tables. (PDF 391 kb)
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